Skip to main content
. 2020 May 13;39(13):e103695. doi: 10.15252/embj.2019103695

Figure 6. PP2A‐B56 is a regulator of ADAM17‐mediated growth factor signaling and tumorigenesis.

Figure 6

  • A
    EGFR activation in the ADAM17 variant expressing DLD‐1 Adam17−/− cells upon H2O2 treatment, determined by Western blot and quantified as the ratio of EGFR autophosphorylated at Tyr1068 to total EGFR. Two‐sided, unpaired Student's t‐test was applied to test for significant differences *P < 0.05, **P < 0.01. Mean and standard deviation indicated from three independent experiments.
  • B, C
    (B) Cell proliferation and (C) Matrigel invasion of the ADAM17 variant expressing DLD‐1 Adam17−/− cells. Two‐sided, unpaired Student's t‐test was applied to test for significant differences *P < 0.05, **P < 0.01. Mean and standard deviation indicated from three independent experiments.
  • D
    Protein expression of the ADAM17 variants in the mouse breast cancer cell line 4T1 Adam17−/−, determined by Western blot. GAPDH was used as an internal loading control.
  • E
    Average tumor volume ± SEM of 4T1 Adam17−/− cells expressing the ADAM17 variants injected into the mammary fat pad of Balb/c mice (n = 10 for each group). Indicated significances are between the I762A and LEE tumors. Two‐sided, unpaired Student's t‐test was applied to test for significant differences *P < 0.05. Mean and standard error of the mean indicated.
  • F
    Survival curve of the tumor bearing mice injected with 4T1 Adam17−/− cells expressing the ADAM17 variants (n = 10 for each group). The indicated significances are between the LEE and wt tumor bearing mice, and the LEE and I762A tumor bearing mice. Log‐rank test was applied to test for significant differences. *P < 0.05.